A multicenter, prospective, open label, randomized controlled phase IIIb study of SHU 508A (Levovist) for doppler signal enhancement in the portal vascular system. - Gebel,M.; Caselitz,M, Bowen-Davies.; Weber,S. (Ultraschall in Med, 1998)